semaj83/ctmatch_classification huggingface dataset:
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Heart Failure, Diastolic Diabetes Mellitus, Type 2 Age > 18 years old but < 75 years old 2. No HF hospitalization within 6 months 3. Overweight or Obesity defined as BMI > 29 but < 40 4. Insulin resistance or T2DM and on oral diabetes agents other than SGLT2i (HgbA1c > 6.5% and < 10.5%) 5. EF calculated based on a recent echo/cath/nuclear study at screening (pre enrollment) > 50% 6. Stable HFpEF (HF with preserved ejection fraction) medications use of 3-6 months with no plans to changes or add medications for at least 12 weeks (course of the study)  Acute HFpEF hospitalization within 6 months of enrollment. 2. CKD stage 4 or 5 (eGFR < 30 ml/min by CKD-EPI equation). 3. Other known causes of HF including poorly controlled hypertension (SBP > 160 mm Hg) or ischemic cardiomyopathy (etc). 4. Anemia (Hgb < 11.5 mg/dL for women and < 12.5 mg/dL for men) or severe thrombocytopenia (platelets < 50,000 mm3) 5. Anticipated changing of HF medication during anticipated study period. 6. HFREF (LV EF < 50%). 7. Acute coronary syndrome, transient ischemic attack, CVA or critical limb ischemia during the last 6 months or coronary/peripheral revascularization within the last 3 months. Severe life threatening illness or live expectancy < 6 months. 8. Contraindications to MRI (metallic implants, severe claustrophobia) or treadmill exercise (limb amputation, severe osteoarthritis or equivalent functional mechanical limitation)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Influenza, Human Missed getting the flu vaccine in the last year No history of reactive airway disease No history of allergy to LAIV No history of allergy to IIV Self-identify as healthy without an immunocompromising condition defined as cancer, autoimmune disease, organ transplant or receipt of steroids  History of reactive airway disease History of allergy to LAIV or IIV Do not self-identify as healthy
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetic Foot Contact Allergy Age of 18 years or older Diagnosed with type 1 or 2 diabetes mellitus Diagnosed with diabetic foot ulcer Provided written informed consent  Patient unwilling or unlikely to comply with the study procedures Patient receiving systemic corticosteroid therapy during PATCH testing (patient should stop with corticosteroid therapy three days before PATCH testing, and may start when testing and reading is done) Patient receiving antihistaminic therapy during PATCH testing (patient should stop with antihistaminic therapy three days before PATCH testing, and may start when testing and reading is done)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 1.0-6.0,  Signs and Symptoms, Respiratory Generally healthy male and female children 6 years of age Children attending kindergarten Signed informed consent by child's parent or legal guardian and willingness to participate in all study activities  Immune dysfunction and/or taking an immunosuppressive medication Child who has received flu vaccination Child who is still breastfed Child taking other food supplements Unable or unwilling to comply with study protocol, including ingesting investigational product, and completing subject dairy Current participation in another clinical study Severe co-morbidity or concomitant disease Concurrent disease or condition, which in the judgment of the investigator, would make the child inappropriate for participation in the study High risk of complications from influenza Allergies to yeast-derived products
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Flu, Human People 65+ otherwise healthy Patients of any age diagnosed with at least one of the following conditions: Diabetes, Asthma, COPD, Coronary Disease or Hearth failure No history of flu vaccination in the previous year  Patients who have been vaccinated against the flu but who have no record of it in the clinical records Patients with contraindications to flu vaccination Patients that cannot be reached either by phone or letter
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-90.0,  Alzheimer Disease Mild Cognitive Impairment Neuropsychiatric Symptoms Sleep Disturbance Males and females of any racial or ethnic group, aged 50-90 (inclusive) Diagnosis of amnestic mild cognitive impairment (aMCI; single or multi domain) or mild AD Subjective complaint of insomnia associated with daytime impairment or distress (ISI ≥ 10) Subjective complaint of sleep disturbance ≥ 3 months in duration Subjective complaint of Neuropsychiatric symptoms (NPI total score ≥ 4) Able to verbalize understanding of involvement in the research and provide written informed consent or provide assent co-signed by a LAR Fluent and literate in English Medications (including any dementia-related meds) stable for at least 4 weeks prior to study baseline Wechsler Memory Scale-Revised Logical Memory II subtest using the following rubric: ≤ 8 for subjects with 16 or more years of education, ≤ 4 for 8-15 years of education, 2 ≤ for 0-7 years of education Global Clinical Dementia Rating (CDR) of 0.5 or 1.0  less than 20 on the Mini-Mental State Examination (MMSE) Acute or unstable chronic illness: including but not limited to: uncontrolled thyroid disease, kidney, prostate or bladder conditions causing excessively frequent urination (> 3 times per night); medically unstable congestive heart failure, angina, other severe cardiac illness as defined by treatment regimen changes in the prior 3 months; stroke with serious sequelae; cancer if < 1 year since end of treatment; asthma, emphysema, or other severe respiratory diseases uncontrolled with medications; and neurological disorders (with the exception of mild AD) such as Parkinson's disease and unstable epilepsy as defined by treatment regimen changes in the prior 3 months; unstable adult onset diabetes as defined by treatment regimen changes in the prior 3 months Use of medication specifically prescribed for sleep disturbance and unwilling or unable to discontinue > one week prior to baseline data collection Current or lifetime history of bipolar disorder History of psychosis preceding onset of memory impairments Substance abuse or dependence Excessive alcohol consumption (>14 drinks per week or > 4 drinks per occasion) Current exposure to trauma, or exposure to trauma within the past 3 months Presence of suicidal ideations representing high risk as measured by the Sheehan-Suicide Tracking Scale (S-STS). Individuals are considered high risk if they endorse a 3 or 4 on questions 2 or 13, or endorse levels 2 or higher on any Question 1a, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 14 Mild traumatic brain injury (history of physical brain injury or blow to the head resulting in loss of consciousness >5 minutes)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Knee Osteoarthritis Arthroplasty Complications Swelling; Leg knee osteoarthritis post-operation of total knee arthroplasty single leg knee arthroplasty  vital signs unstable uncontrolled blood pressure diabetes mellitus neoplasm neurological disorder fibromyalgia cardiac pacemaker musculoskeletal involvement other than TKA
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Cystic Fibrosis Patients must meet the following to participate in this study: 1. Males and females age 18 years and above in Germany and Israel; in countries where permitted, males and females age 16 years and above 2. A confirmed diagnosis of nmCF with a documented G542X mutation, homozygote, or compound heterozygote with one of the specified mutations. For heterozygotes, one mutation has to be G542X, and the second mutation could be and Class 1 or Class 2 mutation, excluding F508del. Patients with one G542X allele and a second allele that is not in the above list may be potentially allowed but only after discussion on a case by case basis with and written approval from the Sponsor. 3. Documented SCC ≥ 60 mEq/L 4. FEV1 ≥ 40% predicted normal for age, gender and height at Screening (Knudson Equation) 5. Body Mass Index (BMI) of 19.0 to 30.0 kg/m2 (inclusive). Patients with any of the following characteristics/conditions will not be included in the study: 1. Participation in clinical study including administration of any investigational drug or device in the last 30 days or 5 half-lives (whichever is longer) prior to investigational product dosing in the current study 2. History of any organ transplantation 3. Major surgery within 180 days (6 months) of Screening 4. Patients without documented prior aminoglycoside exposure who have a mitochondrial mutation that has been shown to increase sensitivity to aminoglycosides 5. Known allergy to any aminoglycoside 6. Patients with any abnormality at ENT screening, that indicates the presence of a vestibular toxicity associated with prior exposure to aminoglycosides. 7. Dizziness Handicap Inventory (DHI)-H score at screening >16 8. Patients receiving CFTR modulators within 2 months of study treatment
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Perineum; Injury primiparous or multiparous women who have never given birth vaginally term patients (after 37 weeks of amenorrhea) patients delivering a fetus in cephalic presentation patients speaking and understanding French  patients suspected of having a fetal macrosomy (greater than the 97th percentile) on the last ultrasound patients with twin pregnancies excised patients patient who has made an acupuncture preparation during pregnancy patients with fetal death in utero patients requiring medical termination of pregnancy
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-51.0,  Flu, Human Influenza, Human Covid19 Age: See above Education: Less than a college degree Gender: Male Race: Caucasian or African American Miscellaneous: Has not received the flu shot in the current flu season yet Miscellaneous: Has sound on his device turned on  Fast survey-taking: subjects who are among the 5% fastest in terms of total time spent on survey within race and treatment group Nonsense answers (those that do not have decipherable English) in the open text sections that suggest low effort Inconsistent responses to questions (such as being willing to give up $10 to receive a flu coupon but not $1) Repeat survey takers as indicated by duplicate emails or IP addresses in survey data
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Food Allergy in Children Subject has signed the informed consent form 2. 18 years of age or older (inclusive) 3. One of the following Diagnostic Categories: 1. Normal healthy controls with no personal or offspring history of food allergy or atopic dermatitis 2. Mother or father without personal history of food allergy, but with a child diagnosed with peanut allergy. Peanut allergy is defined as fulfilling one of the following 3 i. Clinical history defined as one of the following occurring within 2 hours of exposure to peanut: 1. Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips-tongue-uvula) 2. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia) 3. Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incontinence) 4. Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting) ii. Positive skin prick testing > 8 mm iii. Positive specific IgE to peanut > 14.0 kUA/L  Has active flare of atopic dermatitis requiring use of bleach baths, topical corticosteroids, topical immunomodulatory agents, or topical antibiotics on the extremity being evaluated 2. Has a skin disease other than AD that might compromise the stratum corneum barrier such as bullous disease, psoriasis, cutaneous T cell lymphoma, Darier's disease, HaileyHailey, or dermatitis herpetiformis 3. Has a current systemic infection requiring use of systemic antibiotics, antiparasitics, antivirals, or antifungals 4. Has a severe concomitant disease or immunosuppression such as lymphoma, HIV, or Wiskott-Aldrich syndrome 5. Has a history of a severe reaction to latex, tape, or adhesives 6. Has used any biologics within 5 half-lives or 16 weeks, whichever is longer 7. Has received immunotherapy in the last 12 months 8. Has used any investigational drugs within 5 half-lives or 8 weeks, whichever is longer 9. Has used anticoagulants, anxiolytics, or antidepressants within 30 days 10. Has used of systemic immunosuppressive drugs including oral steroids within 30 days 11. Has received total body phototherapy (e.g., ultraviolet light B [UVB], psoralen plus ultraviolet light A [PUVA], tanning beds [>1 visit per week]) within 30 days 12. Is pregnant or lactating (this will be self-verified by the patient)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Aging Sleep Disorder Sedentary (≤ two exercise sessions per week for the past 6 months) 2. Aged 50 to 75 years old 3. Cleared by primary care physician or other personal physician to participate in a 12-week moderate-intensity walking exercise program. Clearance can be provided to one of the study investigators either verbally or in writing  History of neurological illness (e.g. poorly controlled epilepsy with >1 seizure per month in the last 6mo, stroke with residual motor language deficits, Multiple sclerosis, Parkinson's disease, clinically diagnosed dementia [defined as score <26 on the Mini-Mental State Examination], head trauma in the preceding 6-months with continued cognitive symptoms, cerebral palsy, brain tumor, normal-pressure hydrocephalus, HIV infection, or Huntington's disease) 2. Untreated Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I disorders (i.e., severe depressive symptoms, substance abuse or dependence) 3. Impaired activities of daily living (ADLs) measured by the Lawton and Brody Self-Maintaining and Instrumental Activities of Daily Living Scale. 4. Inability to safely exercise or perform any of the tests 5. Inability to perform the cognitive tests due to lack of English proficiency 6. Known diagnosis of severe sleep apnea (apnea-hypopnea index ≥ 15/hour of sleep) 7. Subject fails Cardiopulmonary Exercise Testing (CPET), i.e. develops symptoms such as shortness of breath, chest pain, palpitations, lightheadedness, or syncope during CPET testing 8. Patients with a pacemaker or an automatic implantable cardioverter-defibrillator
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 4.0-6.0,  Immunization The investigator believes that the parents/LAR(s) of the child can and will comply with requirements of the protocol (e.g. understanding of study procedure, consent process, availability at visits) Written informed consent obtained from parent(s)/LAR(s) of the subject Age from 4y+ 1day up to 6 years (until the day they turn 7y) at time of V1 (first immunisation visit) Born to two white Caucasian (of European descent) parents Participant is healthy as determined by general health assessment Have received all the vaccines specified in the UK immunisation schedule Group 1: Never received the intranasal flu vaccine before Group 2: Must have had at least 1 dose of the intranasal flu vaccine Group 3: Must have had at least 2 doses of the intranasal flu vaccine Group 4 : Must have had at least 3 or 4 doses of the internasal flu vaccine  Use (or planned use) of any non-registered or investigational product in 30 days before or after study vaccination Chronic serious medical conditions which may, in the opinion of the investigator, interfere with evaluation of study objectives e.g. chronic lung disease, chronic liver/renal disease, chronic renal failure chronic heart disease, congenital genetic syndromes (e.g. Trisomy 21) Recommended for inactivated influenza vaccine in UK (e.g. Children in clinical risk groups as specified by Public Health England) according to the Green Book, DoH Meets any contraindications to vaccination as outlined in the Green Book, DoH Suspected or confirmed immunosuppressive or immunodeficiency conditions (including splenic dysfunction & HIV) Autoimmune conditions (e.g. Type 1/2 diabetes mellitus, thyroid disease, juvenile idiopathic arthritis) and bleeding disorders Use of systemic steroids for more than one week e.g. prednisolone >0.5mg/kg/day in the three months prior to first study intervention Chronic administration (≥14 days in total) of immunosuppressant's or other immune modifying drugs in the 3 months prior to first study intervention Receipt of blood, blood products and/or plasma derivatives or any immunoglobulin preparation in the three months prior to first study intervention Temporary Participants who have experienced fever (≥38.0°C) or coryzal symptoms within the 24 hours prior to first study intervention
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Exercise Lactate Consenting adults ≥ 18 years old 2. Healthy with no other previous medical history 3. Able to perform moderately intensive exercise without difficulty for at least 30 minutes continuously, and engages in regular aerobic exercise at least twice a week  Active inflammatory skin condition such as eczema or dermatitis 2. Active soft tissue infection or infection at any site 3. Known hypersensitivity to any microneedle component or dressings 4. Presence of any implantable electronic devices such as a pacemaker or stimulators
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-5.0,  Cow Milk Allergy Food Allergy IgE mediated cow's milk allergy suspected for a cow's milk allergy, but with negative diagnosis (e.g. non-IgE mediated cow's milk allergy) IgE mediated food allergy other than cow's milk healthy brothers and sisters from the first three groups  children of 5 years or older